Gilead Sciences, Inc. (GILD): A Bull Case Theory [Yahoo! Finance]
Gilead Sciences, Inc. (GILD)
Last gilead sciences, inc. earnings: 4/30 04:01 pm
Check Earnings Report
US:NASDAQ Investor Relations:
investors.gilead.com
Company Research
Source: Yahoo! Finance
Gilead Sciences, Inc.'s share was trading at $141.95 as of January 30th. GILD's trailing and forward P/E were 21.60 and 15.87 respectively according to Yahoo Finance. BlurryMe/Shutterstock.com Gilead Sciences (GILD), historically a leader in HIV and hepatitis C treatments, is now positioning oncology as its next growth engine through a strategy focused on licensing and targeted acquisitions rather than large-scale buyouts. The company's approach emphasizes “precision oncology,” matching therapies to patients whose tumors carry specific genetic vulnerabilities, which can enhance efficacy and justify premium pricing. A recent agreement with Repare Therapeutics exemplifies this strategy, expanding Gilead's pipeline in DNA-repair-targeted cancer therapies. If its existing oncology drug Trodelvy achieves projected growth and multiple licensed programs reach commercialization, analysts estimate that oncology could contribute several billion dollars in annual revenue by the latter half
Show less
Read more
Impact Snapshot
Event Time:
GILD
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
GILD alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
GILD alerts
High impacting Gilead Sciences, Inc. news events
Weekly update
A roundup of the hottest topics
GILD
News
- Truist Securities Raises Price Target on Gilead Sciences, Inc. (GILD) to $145, Keeps Buy Rating [Yahoo! Finance]Yahoo! Finance
- Gilead Sciences Oncology Update After Positive Trodelvy Keytruda Trial Results [Yahoo! Finance]Yahoo! Finance
- UBS Turns More Bullish on Gilead Sciences, Inc. (GILD) Amid Positive Pharma Sector Outlook [Yahoo! Finance]Yahoo! Finance
- Gilead Sciences (NASDAQ:GILD) had its price target raised by analysts at Leerink Partners from $114.00 to $146.00. They now have an "outperform" rating on the stock.MarketBeat
- Gilead Sciences (NASDAQ:GILD) had its price target raised by analysts at TD Cowen from $125.00 to $145.00. They now have a "buy" rating on the stock.MarketBeat
GILD
Earnings
- 10/30/25 - Beat
GILD
Sec Filings
- 1/29/26 - Form 4
- 1/28/26 - Form 144
- 1/26/26 - Form 4
- GILD's page on the SEC website